Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma;Langzeitergebnisse der adjuvanten chemotherapie nach therapeutischer lymphknotendissektion beim malignen melanom der haut

Hautarzt

Volumn 53, Issue 8, 2002, Pages 536-541

  Kretschmer, L ^a   Helmbold, P ^b   Emmert, S ^a   Marsch, W C ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Adjuvant chemotherapy; Lymph node; Melanoma; Palpable metastases

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; DACARBAZINE; FLUOROURACIL; HYDROXYUREA; VINCRISTINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; SIDE EFFECT; SKIN CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0036934399     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-002-0398-9     Document Type: Article

References (35)

1. The Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63:1676-1680
2. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
3. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA (1981) A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388
4. Bellet RE, Mastrangelo MJ, Berd D (1979) Chemotherapy of metastatic malignant melanoma. In: Clark WH, Goldmann LI, Mastrangelo MJ (eds) Human malignant melanoma. Grune and Stratton, New York London Toronto Sydney San Francisco, pp 325-352
5. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358:866-869
6. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F (1998) Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351:793-796
7. Cascinelli N, Vaglini M, Nava M et al. (1984) Prognosis of skin melanoma with regional node metastases (stage II). J Surg Oncol 25:240-247
8. Coit DG, Rogatko A, Brennan MF (1991) Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 214:627-636
9. Cox DR (1972) Regression model and life tables. J Royal Stat Soc 34:187-220
10. Creagan ET, Dalton RJ, Ahmann DL et al. (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783
11. Czarnetzki BM, Aragon V, Brocker EB, Krieg V, Bunte H, Macher E (1986) Adjuvante Polychemotherapie zusätzlich zur radikalen operativen Behandlung regionaler Lymphknotenmetastasen beim malignen Melanom. Dtsch Med Wochenschr 111:732-736
12. Dessureault S, Soong SJ, Ross MI et al. (2001) Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8:766-770
13. Day CL Jr, Sober AJ, Lew RA et al. (1981) Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 47:955-962
14. Eggermont AM (2000) Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res 157:178-189
15. Eggermont AM (2001) The role interferonalpha in malignant melanoma remains to be defined. Eur J Cancer 37:2147-2153
16. Fiedler H, Hetschko I, Wohlrab W, Wozniak KD, Lübbe D, Taube KM (1990) Ergebnisse einer randomisierten Polychemotherapiestudie beim malignen Melanom. Hautarzt 41:369-374
17. Fortner JG, Woodruff J, Schottenfeld D, Maclean B (1977) Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg 186:101-103
18. Garbe C, Guenther-Eymann K, Stadler R, Orfanos CE (1988) Adjuvante Chemotherapie des malignen Melanoms mit DTIC. Wirkungslosigkeit im Stadium I, mögliche Verbesserung der Überlebensprognose im Stadium IIb. Hautarzt 39:205-212
19. Hancock BW, Wheatley K, Harrison G, Gore M (2001) 37th Ann. Mtg. ASCO, San Francisco, CA, USA, May 12-15, 2001. Proc Am Soc Clin Oncol 20, Pt. 1, Abstr. No. 1393
20. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-486
21. Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S911/C9190. J Clin Oncol 18:2444-2458
22. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380
23. Kirkwood JM, Manola J, Ibrahim JG, Sondak VK, Ernstoff MS (2001) Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma. Proc ASCO 20:1395 (Abstr)
24. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
25. Kissin MW, Simpson DA, Easton D, White H, Westbury G (1987) Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 74:1023-1026
26. Kretschmer L, Neumann C, Preußer KP, Marsch WC (2001) Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin - an analysis of survival and local recurrence. Acta Oncol 40:72-78
27. Kretschmer L, Preußer KP, Marsch WC, Neumann C (2000) Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma. Melanoma Res 10:483-489
28. Kretschmer LW, Preußer KP (2001) Standardized axillary lymphadenectomy improves local control but not survival in patients with palpable lymph node metastases of cutaneous malignant melanoma. Langenbecks Arch Surg 386:418-425
29. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH (1991) Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491-499
30. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K (1994) Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 73:2119-2130
31. Starz H, De Donno A, Balda BR (2001) The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 8:48S-51S
32. Thompson JF (2001) The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol 8 [9 Suppl]:44S-47S
33. Tillman DM, Aitchison T, Watt DC, MacKie RM (1991) Stage II melanoma in the west of Scotland, 1976-1985: prognostic factors for survival. Eur J Cancer 27:870-876
34. Veronesi U, Adamus J, Aubert C et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl Med 307:913-916
35. Zaumseil RP, Wohlrab W, Fiedler H, Wozniak KD (1981) Adjuvante Chemotherapie des malignen Melanoms nach präoperativer Sensitivitätstestung. Folia Haematol Int Mag Klin Morphol Blutforsch 108:721-724